Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)

Sponsor
Raivotech (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06027047
Collaborator
(none)
50
4.5

Study Details

Study Description

Brief Summary

Sleep is not simply the absence of wakefulness. Sleep is an active procedure, normally happening every night, and is absolutely vital. Good sleep is essential for our well-being. Survival without food can be further than without sleep. Work time and commuting time seem to affect total sleep time and night bedtime. Social and work obligation can, therefore, suppress sleep time. Sleep deprived individuals may be facing anxiety and depression symptoms.

The aim of this study is to investigate the presence of anxiety and depression symptoms among adults with the use of the smartphone application Onar. Onar app will be used to gather information from wearable devices of the users including total sleep time, sleep efficiency, wake after sleep onset time. An established questionnaire (Hospital Anxiety Depression Scale/ HADS) will be used to quantify and detect the presence of anxiety and depression in the study population.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jan 15, 2024

Outcome Measures

Primary Outcome Measures

  1. To determine the existence of depression and anxiety symptoms in the study population. [2 weeks]

    Comparison of HADS score with population standardized mean value.

Secondary Outcome Measures

  1. Correlation of depression and anxiety symptoms with Total sleep time (TST). [2 weeks]

    Total sleep time (TST).

  2. Correlation of depression and anxiety symptoms with Wake after sleep onset time (WASO). [2 weeks]

    Wake after sleep onset time (WASO).

  3. Correlation of depression and anxiety symptoms with Sleep Onset Latency (SOL). [2 weeks]

    Sleep Onset Latency (SOL).

  4. Correlation of depression and anxiety symptoms with Epworth Sleepiness Scale (ESS). [2 weeks]

    Epworth Sleepiness Scale (ESS).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Acceptance of terms of use of the application must be done prior to participation in the study.

  • Male and female adults aged ≥18 years old and ≤60 years old.

  • Subjects using the application on a daily basis for at least 1 week prior to participation.

Exclusion Criteria:
  • History of alcohol or other substance abuse.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Raivotech

Investigators

  • Principal Investigator: Kyriakos Karkoulias, Prof., University Hospital of Patras, Greece

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Raivotech
ClinicalTrials.gov Identifier:
NCT06027047
Other Study ID Numbers:
  • ROA101
First Posted:
Sep 7, 2023
Last Update Posted:
Sep 7, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Raivotech
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 7, 2023